Industry & Policy News

[UC San Diego] Pettus, an associate professor of medicine and board-certified endocrinologist who specializes in treating diabetes at UC San Diego Health, is leading a study on Liver Targeted Insulin in type 1 diabetes. The Leona M. and Harry B. Helmsley Charitable Trust recently provided a grant of more than $2 million to UC San Diego to support the research effort.

[Queen's University] Queen’s Health Sciences researchers are part of a multi-institutional research team that will receive $2.4 million to advance cancer research and treatment. The collaborative team – led by principal investigators at Sunnybrook Research Institute and Princess Margaret Cancer Centre – is behind one of five projects to receive funding in the 2023 Terry Fox New Frontiers Program Project Grant competition.

[Curi Bio] Curi Bio announced two recent SBIR grants worth $4.4 million from the National Institutes of Health (NIH) to support its pioneering work on implementing human models to advance discovery of the next generation of medicines.

[Fierce Biotech] After a six-month wait, Fulcrum Therapeutics’ sickle cell disease plans are back on track after the FDA lifted a hold on the biotech’s candidate. The regulator instigated the full clinical hold on the therapy, dubbed FDX-6058, back in February.

[Nature] The US government has extended for six months a key symbolic agreement to cooperate with China in science and technology.

[Taysha Gene Therapies, Inc.] Taysha Gene Therapies, Inc. announced the U. FDA has granted Fast Track Designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.